{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-25-000068","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.591510+00:00","generated_at":"2026-05-17T19:32:52.078382+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Keros Q2 net loss narrows to $30.7M; Board plans $375M capital return to stockholders","bullets":["Net loss of $30.7M in Q2 2025 improved from $45.3M in Q2 2024, driven by Takeda license revenue.","Cash and cash equivalents $690.2M at June 30, 2025, up from $559.9M at Dec 31, 2024.","Board approved return of $375M excess capital to stockholders; cash runway into H1 2028.","Lead asset KER-065 progressing toward Phase 2 trial in Duchenne muscular dystrophy starting Q1 2026.","R&D expenses $43.5M, G&A $14.5M for Q2 2025; both increased vs year-ago period."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-25-000068","json":"https://secwatch.observer/filing/0001664710-25-000068.json","markdown":"https://secwatch.observer/filing/0001664710-25-000068.md","text":"https://secwatch.observer/filing/0001664710-25-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000068/0001664710-25-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471025000068/kros-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:32:52.078382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}